A Trump administration plan to lower drug costs for seniors on Medicare could end up forcing seniors to pay hundreds of dollars more for their arthritis medication, according to a new analysis.
The pharma-funded study from the consulting firm Avalere Health found that Medicare patients with rheumatoid arthritis could pay more for their drugs due to a proposal in the administration’s blueprint released last May to tackle high drug prices.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.
